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A B S T R A C T
The complexation of Cm(III) with human serum albumin (HSA) was investigated using time-resolved laser
fluorescence spectroscopy (TRLFS). The Cm(III) HSA species is dominating the speciation between pH 7.0 and
9.3. The first coordination sphere is composed by three to four H2O molecules and five to six coordinating
ligands from the protein. For the complex formation at pH 8.0 a conditional stability constant of
logK=6.16 ± 0.50 was determined. Furthermore, information on the Cm(III) HSA binding site were obtained.
With increasing Cu(II) concentration the Cm(III) HSA complexation is suppressed whereas the addition of Zn(II)
has no effect. This points to the complexation of Cm(III) at the N-terminal binding site (NTS) which is the
primary Cu(II) binding site. NMR experiments with Cu(II), Eu(III) and Am(III) HSA show a decrease of the peak
assigned to the His C2 proton of His 3, which is part of the NTS, with increasing metal ion concentration. This
confirms the complexation of Eu(III) and Am(III) at the Cu(II) binding site NTS. The results presented in this
study contribute to a better understanding of relevant biochemical reactions of incorporated actinides.
1. Introduction
Accidentally released radionuclides, in particular actinides, can
cause a serious health risk upon incorporation. Apart from the chemical
toxicity, their hazardousness depends mainly on the high radiological
toxicity [1]. Actinides have no essential function in the biochemistry of
the human body and up to now little is known about the mechanisms of
uptake, transport and storage in man. Regarding the development of
potential decontamination therapies, a detailed understanding of the
relevant biochemical reactions of incorporated actinides is strongly
required [2].
Incorporated actinides preferentially interact with blood serum
components before accumulating in the organs (bone, liver, kidneys
etc.) [3,4]. One representative of utmost importance is human serum
albumin (HSA), the most abundant protein in the human blood plasma
(~60% of total protein, 3.5–5 g/dL) [5]. HSA is a single-chain protein
with a molecular mass of 66.5 kDa. It consists of three homologous
domains, each comprised of two subdomains with mainly α-helices
connected by flexible loops [6,7]. Besides its contribution to the reg-
ulation of the colloid osmotic pressure, HSA binds and transports a
range of predominantly water-insoluble molecules such as fatty acids,
hormones, bilirubin, heme, drugs as well as metal ions (such as Na+,
Ca2+, Cu2+ and Zn2+). Although there is still a lack of detailed
structural information, it is known that most mammalian albumins
including HSA have at least four metal ion binding sites: the amino
terminal Cu and Ni binding site (ATCUN site, also known as N-terminal
site, NTS), the Multi-Metal Binding Site (MBS, also known as Site A),
the site around Cys-34 and Site B, which location is still unknown
[6–11]. The NTS or ATCUN site is composed of the first three amino
acids Asp-Ala-His of the albumin sequence [6,7]. Probably the fourth
residue, Lys, is also involved in metal ion binding [12]. An important
characteristic of the NTS is the involvement of nitrogen of the peptide
bonds in the coordination of metal ions. Together with the N-terminal
NH2 group and His-3 a square-planar complexation environment for
metal ions like Cu(II) and Ni(II) is formed [13]. At Site A two His re-
sidues (His-67 and His-247), Asn-99 and Asp-249 are involved in metal
ion binding [8,14]. Since many different metal ions bind to Site A, it is
also known as “multi-metal binding site”, MBS. It is the preferential site
for Zn(II) and one of two favoured sites for Cd(II) binding [15–17].
Furthermore, the MBS can also bind Cu(II) and Ni(II) to a certain extent
[16,18]. The site around Cys-34 and site B which is the second Cd(II)
site are less well characterized. The preferences of several transition
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metal ions for the different HSA binding sites are described in the lit-
erature [18–26]. However, a quantitative comparison of the data is
difficult since the interaction mechanisms are complicated and different
methods and conditions were applied for the determination of the
stability constants. Nevertheless, a list of relative affinities of Cu(II), Ni
(II), Zn(II), Co(II), Cd(II) and V(IV)O to the HSA binding sites NTS, MBS
and Site B has been derived: [19].
NTS: Cu(II) VO(IV) Ni(II) Co(II)
> > > >MBS: VO(IV) Cu(II) Zn(II) Cd(II) Ni(II) Co(II)
>Site B : Cd(II) Co(II)
* High uncertainty of the binding affinity of Zn(II) at this site.
It is well-known that HSA forms complexes with a wide range of
metal ions, especially transition metals. However, up to now only very
few data regarding the interaction of lanthanides and actinides with
albumin is reported [27–34]. Most of them are phenomenological stu-
dies using methods like UV/Vis spectroscopy, FT-IR spectroscopy,
fluorescence spectroscopy and equilibrium dialysis. They give only
semiquantitative results and provide no information on the complexa-
tion mechanism, binding structure and number of species. Schomäcker
et al. derived conditional stability constants for HSA complexes of the
lanthanides Ce, Nd, Eu, Dy, Ho, Er and Tm at pH 7.4, T=310 K and
physiological ionic strength (150mM) using equilibrium dialysis [30].
The logK values increase with decreasing ionic radius of the Ln(III) ions
from 4.90 (Ce(III)) to 8.90 (Tm(III)). Regarding the actinides, only the
interaction of Th(IV) and U(VI) with HSA has been investigated so far.
Michon et al. identified two binding sites for U(VI) using fluorescence
quenching methods [33]. The stronger site seems to be the NTS, for
which a stability constant of logK= 10.8 (pH 7.4) was determined by
Montavon et al. [32] Ali et al. showed that U(VI) and Th(IV) (as well as
Ce(IV)) interact with carbonyl and amide groups of HSA, with U(VI)
showing a slightly higher binding affinity than Th(IV) [31]. Further-
more, Ce(IV), Th(IV) and U(VI) seem to alter the secondary con-
formation of HSA. Circular dichroism measurements show a decrease of
the α-helix content indicating a partial unfolding of the protein.
Most studies on HSA interaction with lanthanides and actinides give
only a qualitative description of the complexation reaction but do not
provide information on the binding site(s) and the detailed structure of
the complexes. Data on the binding of trivalent actinides with HSA is
not available. In the present study Cm(III) is used as a representative of
the trivalent actinides because of its excellent fluorescence properties
[35]. The interaction of HSA with Cm(III) is studied using time-resolved
laser fluorescence spectroscopy (TRLFS). This is a very sensitive method
for determination of the speciation of lanthanides and actinides in
submicromolar concentration ranges [36]. Shape and position of the
emission bands as well as the fluorescence lifetime provide information
on the coordination environment of the metal ion. The present work
focuses on the interaction of Cm(III) with HSA as a function of pH,
temperature and protein concentration to identify and characterize the
Cm(III) HSA species. Furthermore, competition titrations with Cu(II)
and Zn(II) provide information on the preferential HSA binding site of
Cm(III). These results are confirmed by NMR (nuclear magnetic re-
sonance) experiments with Cu(II), Eu(III) and Am(III) albumin, yielding
further insight into the structures of the different complexes.
2. Experimental
2.1. Chemicals and sample preparation
The protein samples were prepared in TRIS (2-Amino-2-(hydro-
xymethyl)propane-1,3-diol) or HEPES (2-[4-(2-hydroxyethyl)piperazin-
1-yl]ethanesulfonic acid) buffered solutions (10mM, pH 7.4) with a
physiological sodium chloride concentration of 150mM NaCl using
ultrapure water (Millipore, Billerica, MA, USA; 18.2MΩ cm). Human
serum albumin of high reagent grade (lyophilized powder, fatty acid
free, globulin free, ≥99%) was purchased from Sigma-Aldrich and
purified before use by size exclusion chromatography (Sephadex G-25
medium, GE Healthcare) and filtration (Amicon Ultra-4 Centrifugal
Filter Units, 30 kDa) according to the protocol of Harris et al. [37,38].
The protein concentration of the HSA stock solution was determined by
UV/Vis spectroscopy at λ=280 nm using an extinction coefficient of
ε=35 296M−1·cm−1 [39].
The Cm(III) stock solution used for the TRLFS studies (c
(Cm)= 2.12·10−5M in H2O) had an isotopic mass distribution of
89.7% 248Cm, 9.4% 246Cm, and≤1% 243Cm, 244Cm, 245Cm and 247Cm.
The Cm(III) concentration of the TRLFS samples was adjusted to
1.00·10−7M by adding 4.7 μl of the Cm(III) stock solution to 970 μl of
the buffered HSA solution with a concentration of 4.85·10−6M, re-
sulting in a final HSA concentration of 5.00·10−6M.
Complexation studies were carried out at varying pH values be-
tween 3.5 and 11.0. The pH was adjusted stepwise starting from pH 7.4
downwards to pH 3.5 and upwards to pH 11.0 using HCl and NaOH
solutions of different concentrations (1.0 M, 0.1M, and 0.01M). For the
titration experiment, the Cm(III) concentration (c(Cm
(III))= 1.00·10−7M) and the pH were kept constant. The HSA con-
centration ranged from 0 to 8.26·10−6M. For the competition titration
experiments, the Cm(III) and HSA concentrations were fixed at c(Cm
(III))= 1.00·10−7M and c(HSA)=5.00·10−6M at pH 8.0. ZnCl2 or
CuCl2 solution (10−2M) was added stepwise up to a total concentration
of c(Cu(II))= 5.00·10−5M and c(Zn(II))= 1.20·10−4M. TRLFS mea-
surements were performed at room temperature (296 K) and physio-
logical temperature (310K). The pH electrode was calibrated at each
temperature.
For the NMR experiments, samples with a total volume of 1ml
containing 1mM HSA and 10mM TRIS in a 9:1 H2O/D2O mixture were
prepared. Deuterium oxide was purchased from Euriso-Top GmbH. The
pH was adjusted to 8.0 and aliquots of a Cu(II), Eu(III) or Am(III) stock
solution were added stepwise until a metal ion concentration of 2mM
was reached. The Cu(II) and Eu(III) stock solutions were prepared from
CuCl2 and EuCl3, respectively (0.1M). For the titration with Am(III), an
aliquot of the Am(III) stock solution, containing 493 μg 243Am(NO3)3
and traces of 241Am(NO3)3 in 0.4 mL 0.5mol·L−1 HNO3 was heated
until dry to reduce the nitrate content. The remaining Am(NO3)3 was
dissolved in 100 μL 0.5mol·L−1 hydrochloric acid to obtain a solution
containing 20mol·L−1 Am(III). After each titration step, the pH was
controlled and a NMR spectrum was recorded. All preparations of
radioactive samples were performed in a dedicated fume hood. Gas-
tight J. Young type NMR tubes were used for radioactive samples.
2.2. Time-resolved laser fluorescence spectroscopy
TRLFS was performed using a Nd-YAG (Yttrium Aluminium
Garnate, Continuum Surelite Laser) pumped dye laser system
(NARROWscan D-R Dye Laser) with a repetition rate of 10 Hz. Cm(III)
was excited using a wavelength of 396.6 nm. Emission spectra were
recorded in the range of 575 to 635 nm after a delay time of 1 μs to
discriminate short-lived fluorescence of organic compounds. After
spectral decomposition by a spectrograph (Shamrock 303i) with a 1199
lines/mm grating, the spectra were recorded with an ICCD (intensified
charge-coupled device) camera (iStar Gen III, ANDOR) containing an
integrated delay controller. For better comparison, all spectra were
normalized to the same peak area. For lifetime measurements, the delay
time between the laser pulse and the detection of the fluorescence
emission was increased continuously with time intervals of Δt= 20 μs.
The lifetime τ is obtained by fitting the fluorescence intensity I as a
function of the delay time t according to
=I I e( ) ( )0
t (1)
with the initial intensity I0 at t=0. The number of water molecules in
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the first coordination sphere is obtained from the fluorescence lifetime τ
(in ms) using the Kimura equation [40,41].
=n 0.65 1 0.88.H O2 (2)
2.3. NMR spectroscopy
All NMR spectra were recorded at T=298 K on a Bruker Avance III
400 spectrometer operating at a resonance frequency of 400.18MHz for
1H nuclei. The spectrometer was equipped with a z-gradient inverse
room temperature probe optimized for 1H detection. Chemical shifts are
referenced internally to TMS (Tetramethylsilane, δ(TMS)= 0 ppm) by
the deuterium lock signal of D2O. For single scan 1H spectra, standard
90° pulse sequences were used. Water suppression was achieved by the
WATERGATE pulse sequence [42,43]. All spectra were recorded with
32 k data points and are zero filled to 64 k points. For WATERGATE
spectra, 64 scans were acquired per spectrum with a relaxation delay of
2 s. Exponential window functions with a line broadening factor of
0.05 Hz were applied for processing.
3. Results and discussion
3.1. Complexation studies of Cm(III) with HSA at varying pH
The normalized fluorescence spectra of Cm(III) with HSA in the pH
range from 3.5 to 11.0 at room temperature (296 K) are shown in Fig. 1.
The spectra reveal a strong pH dependency of the complexation reac-
tion. Up to pH 6.7 the spectrum is dominated by the fluorescence of the
Cm(III) aquo ion, displaying an emission band at λmax= 593.8 nm
[44–46]. With increasing pH the emission band shifts to higher wave-
lengths. Simultaneously, the emission band broadens, which indicates
the presence of at least two different Cm(III) species. Comparison with
Cm(III) spectra measured in the absence of HSA (data not shown) shows
that the main contribution to the emission band results from Cm(III)
interaction with the solvent TRIS-H2O-OH– (λmax= 598.3 nm). Fur-
thermore, at pH≥6.0 a Cm(III) HSA species is formed
(λmax= 602.6 nm). The ratio of this species increases with increasing
pH. Due to the increasing OH– concentration, a continuous shift of the
emission band up to 603.0 nm at pH 9.3 is observed. Above pH 9.7 the
intensity decreases significantly and the emission band broadens due to
the hydrolysis of Cm(III). However, a significantly higher drop of in-
tensity would be expected if only Cm(III) hydrolysis species are present,
indicating the existence of ternary Cm(III)-OH-HSA species. This shows
that the complexation of Cm(III) with HSA plays a significant role in the
alkaline pH region as well.
The shift of the emission band of a Cm(III) complex species relative
to the emission band of the Cm(III) aquo ion results from an increased
ligand field splitting of the complex species and is related to the com-
plexation strength of the ligands. The emission band of the Cm(III) HSA
species is shifted about 10 nm relative to the aquo ion. As shown in a
recent study for Cm(III) transferrin (λmax= 619.9 nm) the internaliza-
tion of Cm(III) into the protein structure upon complexation at the
transferrin binding sites results in a significantly higher bathochromic
shift [47]. Therefore, an internalization of Cm(III) into the HSA protein
structure can be excluded. Instead, the Cm(III) HSA complexation is
characterized by inner-sphere complex formation resulting from the
interaction of Cm(III) with amino acid residues of the protein.
The fluorescence spectra of the three components were determined
from the pH dependent fluorescence spectra (Fig. 2). These represent
the Cm(III) aquo ion, the Cm(III) TRIS/OH– solvent species and the Cm
(III) HSA species. The fractions of these species at various pH values
were determined by peak deconvolution (species distribution, Fig. 3).
Since the total fluorescence intensity is constant during the experi-
ments, the fluorescence intensity factors (fi= Icomplex/Iaquo ion) of the
Fig. 1. Normalized fluorescence spectra of Cm(III) with HSA in the pH range
between 3.5 and 11.0; c(Cm)=1.0∙10−7M, c(HSA)=5.0∙10−6M, TRIS
10mM, NaCl 150mM, T=296 K.
Fig. 2. Normalized fluorescence spectra of the Cm(III) aquo ion, the Cm(III)
TRIS/OH– solvents species and the Cm(III) HSA species.
Fig. 3. Speciation of Cm(III) with HSA as a function of pH; c
(Cm)= 1.0∙10−7M, c(HSA)=5.0∙10−6M, TRIS 10mM, NaCl 150mM,
T=296 K.
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different species are assumed to be 1. Therefore, the fractions of the
peak areas equal the species concentrations. The Cm(III) aquo ion
dominates the speciation up to pH 6.8. The Cm(III) TRIS/OH– solvent
species is present over a wide pH range up to pH 8.3 and reaches a
maximum ratio of about 40% at the physiological pH 7.4. The Cm(III)
HSA species is formed in the pH range from 4.0 to 11.0 and becomes the
dominating species between pH 7.4 and 8.7. At pH≥8.3 ternary Cm
(III)-OH-HSA species are formed and dominate the speciation at
pH≥9.3.
In order to characterize the Cm(III) HSA species, the fluorescence
lifetime was determined. As the species does not exist as a pure com-
ponent at any pH value between 6.0 and 9.0 the decay of the fluores-
cence emission of Cm(III) as a function of the delay time was fitted
using a bi- or triexponential decay function (depending on the pH)
considering the fluorescence lifetimes of the Cm(III) aquo ion
(τ=65 μs), the Cm(OH)2+ (τ=72 μs) and Cm(OH)2+ (τ=80 μs)
species [48,49]. This procedure yields an average fluorescence lifetime
of τ=152 ± 10 μs for the Cm(III) HSA species. Assuming an overall
coordination number of nine for Cm(III), the fluorescence lifetime
corresponds to three to four H2O molecules and five to six coordinating
ligands in the first coordination sphere of Cm(III) [40,41]. These are
mainly amino acids from the protein and potentially additional anions
like OH−, CO32– etc. The fluorescence lifetime of the Cm(III) HSA
species is significantly shorter compared to that of the Cm(III) trans-
ferrin species with complexation of Cm(III) at the C-terminal binding
site of transferrin (τ=220 μs) [47]. Complexation of Cm(III) at the
transferrin binding site leads to an “internalization” of Cm(III) into the
protein structure. The majority of the water molecules in the first co-
ordination sphere are replaced by coordinating ligands from the protein
and carbonate ions as synergistic anions resulting in a significantly
longer fluorescence lifetime. In case of the Cm(III) HSA species there
are still three to four water molecules present in the first coordination
sphere confirming the formation of a comparably weaker inner sphere
complex with the protein. This is in good agreement with the spectro-
scopic shift of the emission band of the Cm(III) HSA species and hints to
binding of Cm(III) at the NTS, since the N-terminal end of the protein
chain is very flexible and easily accessible.
3.2. Complexation studies of Cm(III) with HSA at varying HSA
concentrations
The complexation of Cm(III) with HSA was studied in dependence of
the HSA concentration (c(HSA)=0–8.26∙10−6M) at a fixed pH of 8.0
(Fig. 4). The spectrum obtained in the absence of HSA represents the
Cm(III) solvent spectrum at pH 8.0 with an emission maximum at
λmax= 598.7 nm. With increasing HSA concentration the ratio of the
Cm(III) HSA species increases, resulting in a continuous shift of the
emission band up to λmax=601.6 nm.
The complexation of Cm(III) with HSA is described by the following
equations:













The equilibrium constant of the Cm(III) HSA species is defined ac-
cording to Eq. 4. Transformation to Eq. 5 gives a linear correlation of
the logarithm of the concentration ratio [CmHSA]/[Cm(III)] and the
logarithm of the free HSA concentration. The slope represents the
number of coordinating ligands in the Cm(III) complex (slope analysis).
For the slope analysis the equilibrium concentrations of Cm(III), HSA
and the Cm(III) HSA species are required. They are calculated using the
species distribution in dependence of the HSA concentration obtained
by peak deconvolution and Eqs. (6) and (7).
= +[Cm(III)] [Cm(H O) ]eq 2 93 (6)
=[HSA] [HSA] –[CmHSA]eq tot (7)
Fig. 5 shows the slope analysis of the Cm(III) HSA complexation.
The linear regression of the double logarithmic plot has a slope of 1.06
indicating the formation of a 1:1 Cm(III) HSA complex. Due to steric
reasons, the coordination of a second protein molecule can be ruled out.
This is comparable to the results obtained for Cm(III) transferrin which
also forms a complex with 1:1 stoichiometry under similar experimental
conditions [50].
Using Eq. (4), the conditional stability constant of the Cm(III) HSA
species is calculated to be logK=6.16 ± 0.50. Since the coordinating
amino acid residues in the Cm(III) HSA complex are not yet explicitly
determined, their pKa values cannot be considered for the calculation of
a pH independent logK value. The relatively large error of the stability
constant is due to the fact that the measurements are performed at
pH 8.0 with the ratio of the Cm(III) aquo ion, which represents [Cm]eq,
being ≤10% for each titration step. Even small changes of± 1% of the
[Cm(H2O)9]3+ fraction and therefore [Cm]eq have a significant impact
on the logarithmic stability constant.
Fig. 4. Normalized fluorescence spectra of Cm(III) with increasing HSA con-
centration at pH 8.0; c(Cm)=1.0∙10−7M, c(HSA)= 0–8.26∙10−6M, TRIS
10mM, NaCl 150mM, T=296 K.
Fig. 5. Double logarithmic plot of the concentration ratio [CmHSA]/[Cm] vs.
[HSA].
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Since Cm(III) and Eu(III) have similar effective ionic radii
(IREu(III) = 0.950 Å, IRCm(III) = 0.98 Å) [51] and comparable chemical
properties, the stability constant of the Cm(III) HSA species is compared
to the logK value of Eu(III) HSA. The latter was determined by equili-
brium dialysis at pH 7.4 and T=310 K to be logK=6.41 ± 0.02 [30].
Although the Eu(III) HSA experiments were performed at different
temperature and pH, both stability constants are in good agreement and
confirm the similar complexation behaviour of trivalent lanthanides
and actinides.
3.3. Complexation studies of Cm(III) with HSA at varying pH and
physiological temperature
In addition to the results obtained at room temperature conditions
shown above, the complexation of Cm(III) with HSA is investigated at
physiological temperature (310 K). Fluorescence spectra are measured
in the pH range from 3.5 to 11.5. They correspond to those obtained at
room temperature and display the emission bands of the Cm(III) aquo
ion at λmax= 593.8 nm, the Cm(III) TRIS/OH– solvent species at
λmax= 598.6 nm, the Cm(III) HSA species at λmax= 603.1 nm and the
ternary Cm(III)-OH-HSA species formed in the alkaline pH region.
The species distribution in dependence of the pH is determined by
peak deconvolution of the pH dependent emission spectra. Fig. 6 de-
picts the formation of the Cm(III) HSA species in dependence of pH at
room temperature and physiological temperature. In comparison to the
results at room temperature, the ratio of the Cm(III) HSA species in-
creases by about 10%. Therefore, the Cm(III) HSA species is the dom-
inating species in a wide range between pH 6.3 and 9.7. Comparison at
physiological pH=7.4 shows an increase of the ratio of the Cm(III)
HSA species from about 50% at room temperature to 70% at physio-
logical temperature. Consequently, the complexation of Cm(III) with
HSA is an endothermic process which means that the formation of the
Cm(III) HSA species plays a more significant role at physiologically
relevant conditions (pH 7.4, 310 K, 150mM NaCl). This is very im-
portant with regard to the distribution of incorporated radionuclides,
especially trivalent actinides, in the human body.
3.4. Competition titration of Cm(III) HSA with Cu(II) and Zn(II)
The TRLFS experiments give a good description of the complexation
of Cm(III) with HSA in dependence of pH, temperature and ligand
concentration. However, HSA possesses at least four metal binding sites
and the binding site for Cm(III) is not yet explicitly defined. The two
binding sites with the highest affinities to metal ions are the N-terminal
Cu and Ni binding site (ATCUN site or NTS) and the multi metal binding
site (MBS), which binds predominantly Cd and Zn.
To identify the HSA binding site for Cm(III) competition titrations
with Cu(II) and Zn(II) were performed. Two samples of Cm(III) with
HSA at pH 8.0 were prepared and aliquots of a CuCl2 or ZnCl2 stock
solution were added stepwise. The emission spectra of the Cu(II) ti-
tration are shown in Fig. 7. The spectrum of Cm(III) at pH 8.0 in the
absence of HSA and Cu(II) displays an emission maximum at
λmax= 598.3 nm and results from the Cm(III) interaction with the
solvent. In the presence of HSA the Cm(III) HSA species is formed and
the emission band shifts to λmax= 601.6 nm. With increasing Cu(II)
concentration the Cm(III) HSA complexation is repressed. The emission
band shifts to lower wavelength with increasing Cu(II) concentration
until the Cm(III) solvens spectrum is obtained at the end of the titration.
These results indicate the complexation of Cm(III) at the predominant
Cu(II) binding site, the NTS. This is in good agreement with the fluor-
escence lifetime of the Cm(III) HSA species displaying four to five water
molecules in the inner coordination sphere which are in line with the
complexation of Cm(III) at an easily accessible HSA binding site located
at the protein surface like the NTS. This is also in good agreement with
the results of Montavon et al. on U(VI) HSA interaction indicating
complexation of U(VI) at the NTS [32].
Additionally, a competition titration with Zn(II) was performed to
verify if Cm(III) complexation also occurs at the MBS (Fig. 8). In con-
trast to the experiments with Cu(II) a backshift of the emission band of
the Cm(III) HSA species to the Cm(III) solvent spectrum is not observed
with increasing Zn(II) concentration. Instead, addition of Zn(II) leads to
a slight bathochromic shift of the emission band of up to 2 nm. This
might be attributed to Zn(II) complexation at a different binding site
which is not occupied by Cm(III), most likely at the MBS. The inter-
action of Zn(II) with amino acid residues of the protein introduces slight
changes in the three-dimensional protein structure and influences the
coordination environment of the Cm(III) HSA species. The results of the
Zn(II) competition titration prove that Cm(III) does not predominantly
bind at the preferential Zn(II) binding site, the MBS.
The competition titrations with Cu(II) and Zn(II) are a valuable
contribution to the identification of the binding site of Cm(III) with
HSA. The results clearly point to a complexation of Cm(III) at the NTS at
the N-terminal end of the protein chain. Nevertheless, experiments are
required to obtain a detailed understanding of the binding mechanism
and structure of the Cm(III) HSA complex.
Fig. 6. Formation of the Cm(III) HSA species as a function of pH at room
temperature and physiological temperature; c(Cm)=1.0∙10−7M, c
(HSA)=5.0∙10−6M, TRIS 10mM, NaCl 150mM.
Fig. 7. Normalized fluorescence spectra of Cm(III) with HSA at pH 8.0 in de-
pendence of the Cu(II) concentration; c(Cm)=1.0∙10−7M, c
(HSA)= 5.0∙10−6M, c(Cu)= 0–5.0∙10−5M, HEPES 10mM, NaCl 150mM,
T=296 K.
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3.5. NMR spectroscopy of Cu(II), Eu(III) and Am(III) HSA
For further confirmation of the NTS being the binding site for tri-
valent actinides NMR experiments were performed with Cu(II), Eu(III)
and Am(III) HSA. As NMR is inherently a rather insensitive method,
higher protein and metal ion concentrations, both in the millimolar
concentration range, had to be used. For this reason, Am(III), which is
available in larger quantities than Cm(III), and Eu(III) as lanthanide
analogue for trivalent actinides were used in the NMR experiments.
There are 16 His residues present in HSA. In NMR spectra the His
protons appear in the aromatic region, approximately between 6 and
8 ppm. The pH dependency of the His signals was studied by Labro et al.
[52]. Bos et al. assigned the signal at 7.5 ppm (pH 8.0) to the His C2
proton of His 3 which is part of the NTS [53]. Addition of Cu(II) to HSA
results in a decrease of the peak intensity of this signal (Fig. 9) in-
dicating an interaction between Cu(II) and the His 3 residue upon
complexation at the NTS.
The peak intensity of the 7.5 ppm signal assigned to the His 3 C2
proton was also investigated at various Eu(III) and Am(III) concentra-
tions (Fig. 10). In both cases a decrease of the peak intensity with in-
creasing metal ion concentration is observed. This indicates an inter-
action of Eu(III) and Am(III) with His 3 upon complexation at the NTS,
which is in excellent agreement with the results of the competition
titrations of Cm(III) HSA with Cu(II) and Zn(II), also pointing to a
complexation of Cm(III) at the NTS.
4. Conclusions
In the present study the Cm(III) HSA interaction was studied. A Cm
(III) HSA species was identified and spectroscopically characterized for
the first time. The Cm(III) HSA species is dominating the speciation
between pH 7.0 and 9.3. The spectroscopic shift of the emission band
and the fluorescence lifetime indicate the formation of a Cm(III) com-
plex with the protein with three to four H2O molecules and five to six
coordinating ligands and/or additional anions in the first coordination
sphere of Cm(III). For the complex formation at pH 8.0 the conditional
stability constant of logK= 6.16 ± 0.50 was determined. Another aim
of this work was the identification of the HSA binding site for trivalent
actinides and lanthanides. Competition titration experiments with Cu
(II) and Zn(II) show that with increasing Cu(II) concentration the Cm
(III) HSA complexation is repressed whereas an addition of Zn(II) to Cm
(III) HSA has no effect. This points to the complexation of Cm(III) at the
NTS which is the primary Cu(II) binding site. These results are sup-
ported by NMR experiments with Cu(II), Eu(III) and Am(III) HSA. The
peak assigned to the His C2 proton of His 3, which is part of the NTS,
decreases with increasing metal ion concentration in all cases. This
confirms the complexation of Eu(II) and Am(III) at the Cu(II) binding
site NTS.
At physiologically relevant pH (7.4) and temperature (T=310 K)
about 70% of Cm(III) are bound to HSA. Since HSA is the most abun-
dant protein in human blood, Cm(III) complexation to HSA is a possible
pathway for the distribution of Cm(III) in particular and trivalent ac-
tinides and lanthanides in general in the human body. Therefore, the
results presented in this study contribute to a better understanding of
Fig. 8. Normalized fluorescence spectra of Cm(III) with HSA at pH 8.0 in de-
pendence of the Zn(II) concentration; c(Cm)=1.0∙10−7M, c
(HSA)=5.0∙10−6M, c(Cu)=0–1.2∙10−4M, NaCl 150mM, T=296 K.
Fig. 9. NMR spectra of Cu(II) HSA at pH 8.0 in dependence of the Cu(II) con-
centration; c(HSA)= 1mM, c(Cu(II))= 0–2mM, TRIS 10mM, 10% D2O,
T=298 K.
Fig. 10. NMR spectra of Eu(III) HSA (top) and Am(III) HSA (bottom) at pH 8.0
in dependence of the metal ion concentration; c(HSA)=1mM, c(Eu(III))= c
(Am(III))= 0–2mM, TRIS 10mM, 10% D2O, T=298 K.
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relevant biochemical reactions of incorporated actinides and can be of
major importance for the future development of potential decontami-
nation therapies.
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